Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Thrombolysis of Urokinase for Minor Stroke (TRUST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04420351
Recruitment Status : Not yet recruiting
First Posted : June 9, 2020
Last Update Posted : June 11, 2020
Sponsor:
Collaborators:
Beijing Tiantan Hospital
Shanghai 10th People's Hospital
General Hospital of Shenyang Military Region
Information provided by (Responsible Party):
Bo Song, The First Affiliated Hospital of Zhengzhou University

Brief Summary:
This trial will enroll patients that have been diagnosed with minor stroke, which has occurred within the past 6 hours. TRUST is a prospective multicenter, randomized, blinded-endpoint study to evaluate the efficacy and safety of Urokinase Thrombolysis for patients with minor stroke.

Condition or disease Intervention/treatment Phase
Minor Stroke Drug: Urokinase thrombolysis Drug: Aspirin;Clopidogrel Phase 3

Detailed Description:

China is currently faced with the heaviest stroke burden due to the tremendous population and susceptibility to cerebrovascular disease. As has been assessed, deaths caused by cerebrovascular disease are three times of cardiovascular disease. Within whole population with cerebrovascular disease, minor stoke have taken a significant part of the disease burden. Thus the population with minor stoke is one of the most important parts in efficient prevention of cerebrovascular disease. According to phase I and II data from national stoke registration in China, 35.25% to 42.23% cases were minor ischemic strokes. However, in clinical practice, the minor ischemic stroke patients are likely to be ignored and some might have poor prognosis. As has been demonstrated by a number of studies, up to one third of the acute non-disabling ischemic stroke without in-time thrombolysis may suffer from disabling or death at 90-day follow-up.

Several studies have demonstrated the potential benefits of thrombolysis compared usually with placebo, including the Third International Stroke Trail ( IST-3, rt-PA to placebo, patients within 3 hours after attack, with blood pressure lower than 185/110mmHg and NIHSS≤5),National Institute of Neurological Disorders and Stroke rt-PA Stroke Study( NINDS, rt-PA to placebo, patients with mild ischemic stroke recognized by 5 different definitions).

Urokinase is a kind of non-selective plasminogen activator, urokinase acted as effective catalyzer in the transferring of both free and protein-binding plasminogen to plasmin, thus inducing thrombolysis. As one of the widely used medication for intravenous thrombolysis in China, urokinase has been suggested the the efficacy and safety for ischemic stroke. With easier availability and lower price, urokinase has provided a promising alternation to patients who need thrombolysis in China, especially in less developed areas. The Chinese guideline for diagnosis and treatment of acute ischemic stroke 2018 has recommended urokinase as an alternation in the treatment of acute ischemic stroke within 6-hour time window as well, if rt-PA is not available or affordable. However, randomized and multicenter clinical trial of urokinase thrombolysis for minor stroke is still vacant, which couldn't provide more persuasive evidence.

TRUST is a prospective multicenter, randomized, single-blind evaluation study to evaluate the efficacy and safety of Urokinase Thrombolysis for patients with minor stroke. The trail will enroll a total of 1002 minor stroke patients within a 6 hour time window with a NIHSS score ≤5 at the time of randomization. Randomization will be 1:1 to Urokinase Thrombolysis (experimental) or Antiplatelet agents (control). Patients will receive 1 million units urokinase dissolved by 100ml saline through intravenous infusion within 30min or oral antiplatelet agents. All patients will undergo CT or MRI before treatment and will undergo the second CT within 36 hours after treatment. Patients will be followed up at 36h, 7d and 90 days. The primary outcome measures including the proportion of patients with a modified Rankin Scale(mRS) of 0 or 1 at 90-day follow-up and the patients with symptomatic intracranial hemorrhage within 36 hours. Secondary outcome measures cover new vascular events, the Progress of MRS score, Neurological impairment, Daily function evaluations, Quality of life assessments, Overall mortality and Adverse events and severe adverse events within 90 days.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1002 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase ⅢB, Prospective, Randomized, Open Label, Blinded-endpoint, Multicenter Trial of the Efficacy and Safety of Urokinase Thrombolysis Comparing With Antiplatelet Agents for Patients With Minor Stroke.
Estimated Study Start Date : June 10, 2020
Estimated Primary Completion Date : September 18, 2021
Estimated Study Completion Date : December 18, 2021

Resource links provided by the National Library of Medicine

Drug Information available for: Urokinase

Arm Intervention/treatment
Experimental: Urokinase thrombolysis
The patients of intervention group will receive 1 millions units urokinase dissolved by 100 saline through intravenous infusion within 30 minutes.
Drug: Urokinase thrombolysis
The patients of intervention group will receive 1 millions units urokinase dissolved by 100 saline through intravenous infusion within 30 minutes.
Other Name: Urokinase

Antiplatelet treatment
The control group will receive antiplatelet agents as decided by the physicians according to Chinese guideline for diagnosis and treatment of acute ischemic stroke 2018
Drug: Aspirin;Clopidogrel
The control group will receive antiplatelet agents as decided by the physicians according to Chinese guideline for diagnosis and treatment of acute ischemic stroke 2018.
Other Name: Antiplatelet treatment




Primary Outcome Measures :
  1. Proportion of patients with a modified Rankin Scale(mRS) of 0 or 1 at 90-day follow-up [ Time Frame: 90 Days ]
    mRS has 0-6 points, the higher the worse outcome.

  2. Proportion of patients with symptomatic intracranial hemorrhage within 36 hours [ Time Frame: 36 hours ]
    Symptomatic intracranial haemorrhage within 36 hours


Secondary Outcome Measures :
  1. Proportion of patients with new vascular events [ Time Frame: 90 days ]
    Proportion of patients with new vascular events within 90 days(Ischemic stroke / hemorrhagic stroke / TIA / myocardial infarction / vascular death)

  2. MRS score [ Time Frame: 90 days ]
    To evaluate the progress of MRS score

  3. The ratio of patients with MRS 0-1 during the last visit in two groups [ Time Frame: 90 days ]
    mRS has 0-6 points, the higher the worse outcome.

  4. Changes in National Institutes of Health Stroke Scale(NIHSS) score [ Time Frame: 90 days ]
    Neurological impairment in two groups (changes in NIHSS score at 90-day follow-up). NIHSS has 0-42 points, the higher the worse outcome.

  5. Barthel index (BI) score [ Time Frame: 90 days ]
    Daily function evaluations(BI score at 90 days). BI has 0-100 points,the higher the bettter outcome.

  6. Quality of life assessments [ Time Frame: 90 days ]
    EuroQol five dimensional questionnaire (EQ-5D scale).

  7. Overall mortality [ Time Frame: 90 days ]
    Overall mortality within 90 days

  8. Adverse events and severe adverse events [ Time Frame: 90 days ]
    Adverse events and severe adverse events in two groups during 90 days



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Adult patients: 18-80 years old
  2. The time from last seen well to treatment < 6 hours
  3. Minor stroke defined as a baseline NIHSS ≤5 at the time of randomization..
  4. First onset or pre-stroke mRS≤1
  5. Informed consent signed

Exclusion Criteria:

1.Hyperdensity on CT suggesting intracranial hemorrhage

2.Large acute stroke >1/3 middle cerebral artery (MCA) territory visible on CT or MRI

3.Other contraindications of intravenous thrombolysis, including but not limited to:

  1. Intracranial tumor, arteriovenous malformation
  2. Coma or confirmed as severe stroke by clinical assessment (e.g. NIHSS ≥25) or proper imaging methods
  3. With seizure
  4. Stroke attack within past three months
  5. Heparin administration within 48h before onset, with APTT longer than upper limit
  6. Stroke history with diabetes
  7. Platelet count ≤100×10^9/L
  8. Difficult to control hypertension, defined by systolic pressure ≥185mmHg or diastolic pressure ≥110 mmHg in 3 tests with at least ten minutes interval, under well guided medications.
  9. Blood glucose <50mg/dl(2.7mmol/l)or >400mg/dl(22.2mmol/l)
  10. Obvious hemorrhage within past 6 months
  11. Oral anti-coagulation drug administration (e.g. warfarin) with INR>1.5
  12. Intracranial hemorrhage or suspected intracranial hemorrhage (including subarachnoid hemorrhage)
  13. Pregnancy or lactation.
  14. History of severe CNS damage (e.g. tumor, arterial aneurysm or CNS surgery)
  15. Hemorrhagic retinopathy, e.g. diabetes (hemorrhages suggested by optic impairment) or other hemorrhagic ocular lesions.
  16. Bacterial endocarditis or pericarditis.
  17. Prolonged or traumatic CPR (>2min), puncture in nonstress vessels within past 10 days, such as subclavian vein puncture.
  18. Acute pancreatitis.
  19. Confirmed ulcerative gastric or intestinal problems within 3 months.
  20. Arterial aneurysm or arteriovenous malformation.
  21. Any tumor that increase risk of hemorrhage.
  22. Severe hepatic diseases, like hepatic failure, liver cirrhosis, portal hypertension, esophageal varices or active hepatitis.
  23. Major surgery, severe trauma or craniocerebral trauma within past 10 days.
  24. Allergy to any components of urokinase.

4.Severe, fatal diseases with less than 3 month expected survival.

5.Intended to receive standard rt-PA thrombolysis or intravascular therapy.

6.Already participating in other studies that conflict to this study.

7.Unable to accomplish the follow-up.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04420351


Contacts
Layout table for location contacts
Contact: Yongli Tao, MD;PhD +86-371-66278068 tyl2112@126.com
Contact: Yafang Xu, MD +86-371-66278067 yafangxu321@163.com

Sponsors and Collaborators
The First Affiliated Hospital of Zhengzhou University
Beijing Tiantan Hospital
Shanghai 10th People's Hospital
General Hospital of Shenyang Military Region
Investigators
Layout table for investigator information
Principal Investigator: Bo Song, MD;PhD The First Affiliated Hospital of Zhengzhou University
Publications:

Layout table for additonal information
Responsible Party: Bo Song, Chief of neurology department, The First Affiliated Hospital of Zhengzhou University
ClinicalTrials.gov Identifier: NCT04420351    
Other Study ID Numbers: 2017YFC1308202
First Posted: June 9, 2020    Key Record Dates
Last Update Posted: June 11, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Bo Song, The First Affiliated Hospital of Zhengzhou University:
Thrombolysis
Urokinase
Ischemic stroke
Additional relevant MeSH terms:
Layout table for MeSH terms
Stroke
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Aspirin
Clopidogrel
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Antipyretics
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents